CG Oncology, Inc.
CGON
$75.03
$0.320.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.16M | 1.08M | 2.32M | 1.67M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.16M | 1.08M | 2.32M | 1.67M | -- |
| Cost of Revenue | 58.58M | 46.69M | 33.03M | 29.46M | 31.33M |
| Gross Profit | -57.43M | -45.61M | -30.71M | -27.80M | -31.33M |
| SG&A Expenses | 28.98M | 20.78M | 17.99M | 23.33M | 17.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.56M | 67.47M | 51.02M | 52.80M | 48.74M |
| Operating Income | -86.40M | -66.39M | -48.70M | -51.13M | -48.74M |
| Income Before Tax | -79.06M | -60.20M | -41.31M | -43.81M | -41.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -79.06M | -60.20M | -41.31M | -43.81M | -41.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.06M | -60.20M | -41.31M | -43.81M | -41.43M |
| EBIT | -86.40M | -66.39M | -48.70M | -51.13M | -48.74M |
| EBITDA | -85.55M | -65.55M | -47.85M | -50.71M | -48.59M |
| EPS Basic | -0.90 | -0.71 | -0.52 | -0.57 | -0.54 |
| Normalized Basic EPS | -0.56 | -0.45 | -0.32 | -0.36 | -0.34 |
| EPS Diluted | -0.90 | -0.71 | -0.52 | -0.57 | -0.54 |
| Normalized Diluted EPS | -0.56 | -0.45 | -0.32 | -0.36 | -0.34 |
| Average Basic Shares Outstanding | 88.20M | 84.52M | 80.06M | 76.73M | 76.23M |
| Average Diluted Shares Outstanding | 88.20M | 84.52M | 80.06M | 76.73M | 76.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |